Plain-English translation of NCT03851640 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a medication called to see if it can help men with advanced prostate cancer (cancer that has spread to other parts of the body) whose cancer has continued to grow despite treatment with abiraterone acetate and docetaxel. About half of participants will receive the new medication, and half will receive a placebo (a pill with no active ingredient), so researchers can fairly compare how well the treatment works.
Men with advanced prostate cancer that no longer responds to standard treatments have very few options left. This medication aims to provide a new way to fight the cancer and help patients live longer when other treatments have stopped working.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to either take capsules or a placebo capsule by mouth. You will visit the research center regularly for check-ups, blood tests, and imaging scans to see how your cancer is responding. The study team will monitor you closely for any side effects and will continue following your health even after the treatment period ends to track how long you survive.
AI-generated summary from trial data · Jul 9, 2026 · Not medical advice
China
Phase
Large-scale testing
Sponsor
Hinova Pharmaceuticals Inc.
Enrollment target
~417 participants
Started
April 2019
Primary completion
September 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Sex
Male only
Last updated on clinicaltrials.gov in March 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Yi Zhou
Hinova Pharmaceuticals Inc.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.